We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Molecular Diagnostic Test Accurately Predicts Therapy Outcomes in Breast Cancer Patients

By LabMedica International staff writers
Posted on 11 Mar 2024
Print article
Image: RNA Disruption Assay is a cancer diagnostic platform measuring tumor response early in cancer treatment (Photo courtesy of Rna Diagnostics)
Image: RNA Disruption Assay is a cancer diagnostic platform measuring tumor response early in cancer treatment (Photo courtesy of Rna Diagnostics)

Breast cancer remains the leading cause of cancer-related deaths among women. In 2022 alone, it accounted for 2.3 million new cases globally, with 670,000 fatalities. As cancer drug development progresses, the demand for diagnostic tools to optimize these treatments is increasingly needed. Studies, both preclinical and clinical, have shown a significant link between the disruption of ribosomal RNA (rRNA) and the effectiveness of treatment. Notably, a lack of RNA disruption is often tied to a poor response to therapy and a grim prognosis. In primary breast cancer, the disruption of tumor RNA by drugs varies according to each individual's tumor biology, regardless of the cancer subtype. Now, a molecular diagnostics test that evaluates tumor response to anti-cancer drug therapy has the potential utility to enable the timely optimization of cancer treatments.

Developed by Rna Diagnostics (Toronto, Ontario, Canada), the RNA Disruption Assay (RDA) is an innovative test designed to measure the extent of RNA disruption in tumor cells. This test can predict, with remarkable accuracy, the likelihood of complete tumor elimination post-treatment in breast cancer patients undergoing pre-operative chemotherapy. Utilizing RDA testing, oncologists can adapt treatment plans based on an early assessment of a patient’s response, enhancing or reducing treatment as needed. Such timely adjustments in pre-operative treatment could not only minimize the adverse effects of ineffective drugs but also improve patient outcomes by switching to alternative treatment regimens.

Rna Diagnostics has recently released phase 1 results of the BREVITY (Breast Cancer Response Evaluation for Individualized Therapy) clinical trial. This trial, part of an international two-phase study conducted across 55 cancer centers in Canada, the United States, Italy, Germany, France, Spain, and Poland, aims to establish the efficacy of RDA in predicting outcomes from pre-operative chemotherapy. Phase 1 involved 80 patients with stage I, II, or III breast cancer, who underwent pre-operative drug treatment followed by surgical removal of the tumor. These initial results show the assay's strong ability to accurately predict treatment outcomes during the therapy course, enabling oncologists to tailor patient care more effectively.

“Our ultimate goal is to personalize breast cancer treatments. If validated, this test has the potential to accurately predict which treatment will be effective for an individual patient,” said Dr. Foluso Ademuyiwa, Co-Chair of BREVITY Steering Committee.

Related Links:
Rna Diagnostics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.